These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9153894)

  • 1. [Efficacy and safety of acarbose treatment of NIDDM].
    Wainstein J; Jedwab M
    Harefuah; 1997 Feb; 132(4):258-63, 311. PubMed ID: 9153894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB; Bray GA
    Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
    Hoffmann J; Spengler M
    Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
    Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
    Hoffmann J; Spengler M
    Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB
    Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
    Bayraktar M; Van Thiel DH; Adalar N
    Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus.
    Noda K; Umeda F; Nawata H
    Diabetes Res Clin Pract; 1997 Aug; 37(2):129-36. PubMed ID: 9279483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
    Josse RG
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acarbose: in search for its real indications in current medical practice.
    Lerman I; Gómez Perez FJ; Aguilar-Salinas CA; Rodrigo JA
    Diabetes Care; 1996 Jan; 19(1):94-5. PubMed ID: 8720547
    [No Abstract]   [Full Text] [Related]  

  • 14. Acarbose in the treatment of type I diabetes.
    Hollander P; Pi-Sunyer X; Coniff RF
    Diabetes Care; 1997 Mar; 20(3):248-53. PubMed ID: 9051366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study.
    Spengler M; Cagatay M
    Clin Invest Med; 1995 Aug; 18(4):325-31. PubMed ID: 8549020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B; Piñol C
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment.
    Leonhardt W; Hanefeld M; Fischer S; Schulze J; Spengler M
    Arzneimittelforschung; 1991 Jul; 41(7):735-8. PubMed ID: 1772463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
    Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
    Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acarbose: a review of US clinical experience.
    Coniff R; Krol A
    Clin Ther; 1997; 19(1):16-26; discussion 2-3. PubMed ID: 9083705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.